Project Call

Funding Announcement For Research On COVID-19 In The Wake Of The Sars-CoV-2 Outbreak

Due to the current outbreak of the corona virus Sars-CoV-2, the German Federal Ministry of Education and Research is opening “Module 3 (Rapid Response) of the funding announcement “Guideline for the funding of a “National Research Network for Zoonotic Infectious Diseases”; Federal Gazette of 15.02.2016.
The relevant points of the funding announcement are specified as follows.
This call for proposals is only valid in conjunction with the above funding regulations.
2 Object of funding
Funding will be provided for individual projects and, in justified exceptions, small research consortia (with up to 3 partners at different institutions), which are oriented towards the WHO’s priority setting ( and intend to conduct research on the following points:
– the biology of the virus and its transmission;
– animal and environmental research on the origin of the virus, including control measures at
the human-animal interface;
– epidemiological studies;
– clinical characterisation and clinical management of diseases caused by the virus;
– infection prevention and control, including the best ways to protect health care workers;
– research and development of drugs and other therapeutic methods and the development of new diagnostic approaches (research into vaccine development and near-market diagnostic development are not covered by the funding);
– accompanying research and ELSA research in connection with the outbreak.
Funding will also be provided for individual projects by German applicants who wish to participate in international research consortia within the framework of the global research response to COVID-19 coordinated by the WHO. An application according to the guidelines
( must be submitted for the German individual project.
Funding for a period of up to 18 months is available in the following modules:
Module 1 – Combating COVID-19 through early clinical studies for the application of already known therapeutic approaches to Sars-CoV-2
Funding will be provided for early phase I, I/II and possibly II clinical studies on therapeutic approaches that have a reasonable chance of being transferrable to Sars-CoV-2.
Module 2 – Control of COVID-19 through new therapeutic and diagnostic approaches
Eligible for funding are:
English translation of excerpts from the BMBF COVID-19 call (202):
The German original version alone shall be legally binding
– clinical studies to expand the diagnostic possibilities for a better understanding of serology
and thus of the course of infection, the effectiveness control of new therapeutic approaches
and the effectiveness of infection and transmission control measures
– the development of therapeutic approaches in the late pre-clinical phase (proof-of-concept
studies) up to the clinical testing of phase I
Module 3 – Research that contributes to the understanding of the virus and its spread
– Research on human pathogenic properties of the virus, infection chains and conditions of
– Approaches for testing the transferability of existing animal models to Sars-CoV-2
– Development of new clinically relevant animal models and human cell models (e.g. lung
infection model)
– Epidemiological approaches
– Infection prevention (without vaccine development) and control, also for the protection of
healthcare workers
– Research on ethical, legal and socio-ecomonic aspects (ELSA) related to the current outbreak
Module 4 – Support of already ongoing research projects on corona viruses
Under Module 4, publicly funded German research projects on coronaviruses and related ELSA research that are already underway can apply for a grant for limited additional work of up to 50,000 euros.
3 Grant recipients
The underlying call for proposal applies
4 Prerequisites for funding
Beneficiaries are obliged to,
– comply with uniform standards for quality assurance of biomaterial banks, patient registers, IT networking, animal studies (including ARRIVE Guidelines1) and when carrying out clinical studies according to international standards (including the Helsinki Declaration, ICH Guideline on Good Clinical Practice, EU Directive 2001/20 / EC), CONSORT statement2;
– comply with internal scientific codes and recommendations for security-related research;
– participate in possible evaluative measures and provide information for evaluating the
success of the funding measure.
For the purpose of better global coordination of the use of funding, the BMBF intends to share relevant application and project data with international sponsors who are WHO-coordinated in GloPID-R3. Applicants must already give their written consent when submitting the application, but can exclude details relevant to patent law from this by highlighting these in the application

English translation of excerpts from the BMBF COVID-19 call (202):
The German original version alone shall be legally binding accordingly.
Funded projects must be application-oriented research and development. Purely or mainly basic research projects cannot be funded.
Further requirements apply to individual modules:
Module 1 – Applicants must plausibly demonstrate how the therapeutic approach can be quickly and reliably introduced into clinical practice.
Purely academic consortia or individual projects must have the consent of any intellectual property rights holders.
Module 2 – For preclinical approaches, it must be plausibly demonstrated that the approaches can be transferred into a phase I clinical trial within 12-18 months from the start of the project.

For more information:

Leave a Comment